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Facioscapulohumeral muscular dystrophy (FSHD) is a progressive
muscle disorder that has been associated with a contraction of
3.3-kb repeats on chromosome 4q35. FSHD is characterized by a
wide clinical inter- and intrafamilial variability, ranging from
wheelchair-bound patients to asymptomatic carriers. Our study is
unique in comparing the gene expression profiles from related
affected, asymptomatic carrier, and control individuals. Our results
suggest that the expression of genes on chromosome 4q is altered
in affected and asymptomatic individuals. Remarkably, the
changes seen in asymptomatic samples are largely in products of
genes encoding several chemokines, whereas the changes seen in
affected samples are largely in genes governing the synthesis of
GPI-linked proteins and histone acetylation. Besides this, the af-
fected patient and related asymptomatic carrier share the 4qA161
haplotype. Thus, these polymorphisms by themselves do not ex-
plain the pathogenicity of the contracted allele. Interestingly, our
results also suggest that the miRNAs might mediate the regulatory
network in FSHD. Together, our results support the previous
evidence that FSHDmaybe caused by transcriptional dysregulation
of multiple genes, in cis and in trans, and suggest some factors
potentially important for FSHD pathogenesis. The study of the
gene expression profiles from asymptomatic carriers and related
affected patients is a unique approach to try to enhance our
understanding of themissing link between the contraction in D4Z4
repeats and muscle disease, while minimizing the effects of dif-
ferences resulting from genetic background.
expression profiling  microarray  skeletal muscle
Facioscapulohumeral muscular dystrophy (FSHD) is an auto-somal dominant disorder, the locus of which has been
mapped to the subtelomeric portion of chromosome 4, at 4q35
(1). This region is characterized by a series of 3.3-kb repeats
termed D4Z4. The D4Z4 array may vary from 11 to more than
100 units in the general population, whereasmost FSHDpatients
have a partial deletion of an integral number of these repeats,
and exhibit 10 or fewer units (2). Similarly sized D4Z4 regions
are observed in affected relative members within families.
FSHD is typically characterized initially by facial muscle
weakness. During progression, weakness and atrophy of shoul-
der girdle muscles is observed in almost all cases. A gradual
spread to abdominal and foot-extensor muscles, followed by
clinical involvement of upper arm and pelvic girdle muscles, is
seen in most patients. Asymmetry of muscle involvement is
common. Among the extramuscular features that may be asso-
ciated with FSHD are retinal abnormalities and high-tone
hearing loss (3). Depression, muscle pain, and fatigue are also
often observed among FSHD patients (4–6).
Although it is not possible to predict the course of the disease,
there tends to be an inverse relationship between the residual
repeat size, the age at onset, and the severity of the disease.
Patients with 1 to 3 repeat units are usually very severely
affected, whereas patients with 4 to 10 repeats tend to have a
milder course (7).
FSHD is also characterized by interfamilial and intrafamilial
variability, with severity ranging from asymptomatic carriers to
loss of ambulation (8). Some families also show clinical antici-
pation, although all affected members carry the same deleted
fragment (9, 10). Males are on average more often and more
severely affected than females, with20% of individuals related
to FSHD patients remaining asymptomatic (11, 12). Further-
more, these nonpenetrant cases seem to be more common in
particular families (13).
Several observations have suggested that FSHD is caused by
a complex and uncommon mechanism. Despite the 98% of
homology between the D4Z4 repeats at 4q35 and 10q26, and the
equal frequency of translocations observed between these 2
regions, FSHD is uniquely associated with contractions on
chromosome 4. Contraction of a translocated 4-type allele on
chromosome 10 does not cause FSHD (14–16). As monosomy of
4qter is not associated with FSHD, it is believed that the
presence of a small number of D4Z4 repeats is crucial to the
process leading to the disease (17). In addition, studies of 4
different polymorphic markers showed that FSHD is restricted
to one specific haplotype at 4q35ter, 4qA161 (18). In addition,
the proximal unit of D4Z4 is significantly hypomethylated in
affected and asymptomatic carriers, while in type-2 FSHD, a
form of the disease that is not linked to contractions of D4Z4
repeats at 4q35, both alleles are significantly hypomethylated (19).
Some studies have proposed that FSHD is caused by the
transcription of a putative gene encoded by the D4Z4 repeats,
termed double homeobox 4 (DUX4) (20, 21). The over-
expression of DUX4 is generally toxic to cells, leading to
apoptosis and activation of PITX1 (paired-like homeodomain
transcription factor 1). Changes in DUX4 or PITX1, both
homeodomain proteins, could explain several of the key features
in FSHD, including the left–right asymmetry, atypical inflam-
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matory responses, and defects in myoblasts reported in FSHD
patients (20, 21). Another model suggests that over-expression of
critical genes upstream of the D4Z4 repeats at 4q35 in FSHD
patients causes a loss of position-effect variegation (22, 23). The
findings that a repressor complex composed of YY1, HMGB2,
and nucleolin bind to D4Z4 and that a nuclear matrix attachment
site (S/MAR), located immediately upstream of D4Z4, dissoci-
ates from the nuclear matrix in FSHD patients, are consistent
with a model for dysregulation of genes in cis as a primary event
in FSHD (24, 25). Data consistent with such dysregulation have
not been supported by several studies using gene array or
quantitative RT-PCR, however.
Despite the substantial effort to elucidate the molecular
mechanism underlying FSHD, the exact mechanism is still
unclear. It is also significant that neither of the proposed
mechanisms can explain the clinical variability characteristic of
FSHD, clinical anticipation, or why some individuals with 10 or
fewer D4Z4 repeats remain asymptomatic. We postulated that
these asymptomatic individuals might provide important clues
about the pathogenesis of FSHD and the molecular mechanisms
to suppress it. To test this, we compared the gene-expression
profiles from affected individuals, asymptomatic carriers, and
normal controls through microarray analysis, looking for genes
that might be implicated in suppression or enhancement of the
disease expressivity. We focused our studies on samples from
related individuals to minimize variations caused by genetic
background. The contribution of microRNAs to FSHD was also
evaluated.
Results
Expression Profiles in Affected Patients and Asymptomatic Carriers.
The gene-expression profiles from 3 related members (affected,
asymptomatic carrier, and control) from 5 different families
were compared through microarrays. Using the criteria de-
scribed in Materials and Methods for microarray data analysis to
identify the differentially expressed genes among affected indi-
viduals, asymptomatic carriers, and normal controls, 180 loci-
annotated probes were found to be significantly dysregulated.
When we compared the expression levels between the affected
and asymptomatic, 147 probes were significantly dysregulated, of
which 13 were up-regulated in affected patients compared to
asymptomatic relatives [supporting information (SI) Tables S1
and S2] . In comparisons of affected individuals and healthy
controls, only 56 probes were differentially expressed, of which
20 were up-regulated in affected relative to controls (Table S3
and Table S4). Comparisons of asymptomatic carriers and
healthy controls identified 12 probes with a significant fold-
change, all of which were up-regulated. Surprisingly, 5 of these
probes represent genes from chromosome 4q (Table 1). The only
gene similarly and significantly dysregulated in affected and
asymptomatic carriers relative to control is IGHA1 (see Table 1),
encoding an Ig heavy chain, suggesting that its up-regulation
might be related to the presence of the FSHD repeat contraction
in these individuals.
The categories of biological processes that our results identi-
fied as altered in FSHD were categorized in the DAVID
program as described in Materials and Methods. The biological
processes most affected in FSHD patients, compared to controls,
are involved in histone acetyltransferase and synthesis of GPI-
anchors (Table 2). In asymptomatic carriers, however, there is a
clear prevalence of processes related to chemokines (see Table
2), and in affected versus asymptomatic samples, most of the
categories are related to regulation of transcription (see Table 2).
Expression of 4q35 Genes. To check if the genes previously re-
ported to be dysregulated from the region in cis to 4q35 are
specifically dysregulated in our affected-patient population, we
compared their expression among our 3 groups of samples.
There was no hybridization signal for 2 genes: DUX4 and FRG2
(Table S5). There were no significant alterations in transcrip-
tional level among affected, asymptomatic, and controls for
FRG1, PDLIM3, andANT1 (see Table S5). However, as reported
elsewhere (21), the probes on U133 Plus 2.0 chip for the DUX4
and FRG1 genes do not target the chromosome 4q35 genes
specifically. The only significant differences in this set of genes
were for ANKRD37 and F11 (see Table S5), which were signif-
icantly dysregulated only in affected patients, compared to
asymptomatic carriers. Their products could be involved in the
pathogenesis of FSHD.
Validation of Microarray Results.Themost interesting dysregulated
genes were in asymptomatic muscle biopsies relative to control
(see Table 1) and were from chromosome 4q. It was necessary
to validate their expression using all possible samples to deter-
mine if these genes would be candidates to suppress the FSHD
phenotype in asymptomatic carriers. (Please note that RNA
samples were not available from all of the original samples used
in generating the microarrays for this purpose). The 4 dysregu-
lated genes from chromosome 4q (CXCL9,CXCL11,LOC91431,
and STATH) were selected along with 2 other genes, the
expression of which appeared more homogeneous among the
samples (PRIC285 and LPP), and also CXCL10, which is clus-
tered between CXCL9 and CXCL11 on 4q21, for validation by
quantitative RT-PCR. Comparisons of the expression levels of
these genes in paired samples from the same family that showed
CXCL9, CXCL10, CXCL11, STATH, and LOC91431 are signif-
icantly up-regulated in asymptomatic carriers compared to af-
fected individuals (Table 3). However, when other samples from
Table 1. Expression fold-changes of significantly dysregulated genes in asymptomatic vs. control
Probe set Gene Loci Fold-change (asy/cont) Fold-change (asy/aff) Fold-change (aff/cont)
217022_s_at IGHA1 14q32.33 13.85 0.69 19.98
203915_at CXCL9 4q21 11.44 1.85 6.19
211122_s_at CXCL11 4q21.2 10.66 8.52 1.25
210163_at CXCL11 4q21.2 8.91 12.13 0.73
205890_s_at UBD 6p21.3 8.60 8.13 1.06
1557690_x_at NPAS2 2q11.2 4.62 4.99 0.92
1558340_at DIXDC1 11q23.1 4.00 5.16 0.78
1565935_at LOC91431 4q25 3.98 4.65 0.86
216968_at MASP2 1p36.3-p36.2 3.98 4.60 0.87
228230_at PRIC285 20q13.33 3.95 4.32 0.91
206835_at STATH 4q11-q13 3.92 3.11 1.26
243874_at LPP 3q28 3.49 4.87 0.72
Underlined fold-changes represent those deemed significant.
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unrelated affected and asymptomatic individuals with different
numbers of residual D4Z4 are included, there is no difference in
the relative expression of those genes by RT-PCR in affected and
asymptomatic groups (Table S6). Interestingly, a graph of these
results, considering the fold-changes for affected and asymp-
tomatic as a function of the residual number of D4Z4 repeats
(Fig. 1), revealed a correlation between the expression levels of
the chemokines and the residual number of D4Z4 in affected
patients, but not in asymptomatic carriers. In contrast, negative
correlations were found for LOC91431 in asymptomatic carriers
(Fig. 2). Given the small sample size available for the validation
through RT-PCR, some of the calculated correlations are not
significant (P  0.05).
Characterization of Polymorphisms from 4q35. As it was previously
reported that only contraction of D4Z4 repeats in 4qA161
haplotype was found to cause FSHD, while contractions in other
common 4q haplotypes are nonpathogenic (18), we tested if the
affected and related asymptomatic individuals, sharing the same
FSHD contraction, have different haplotypes that could be
associated with the expression of the disease. We examined
several polymorphisms on 4qter: the subtelomeric variations
distal to D4Z4 (A and B), which can be distinguished by the
presence of a beta satellite DNA on A-type alleles, the G/C SNP
within the most proximal D4Z4 unit, and a simple sequence-
length polymorphism (SSLP) located 3.5-kb proximal to D4Z4.
The polymorphisms, when compared in affected and related
asymptomatic carriers, can determine their correlation with the
pathogenicity of the contracted allele. All tested individuals
Table 2. Gene ontology (GO) categories enriched in the set
of differentially expressed genes (P < 0.05) ranked by the
fold-enrichment
GO category Fold enrichment
Affected vs. Control
Histone acetyltransferase binding 80.6
GPI anchor metabolic process 32.9
GPI-anchor biosynthesis 32.3
Phosphoinositide metabolic process 16.7
Lipoprotein metabolic process 13.4
Glycerophospholipid metabolic process 12.2
Glycan structures– biosynthesis 2 11.1
Membrane lipid biosynthetic process 9.5
Nucleolus 7.0
Membrane lipid metabolic process 6.0
Cell adhesion 5.3
Intracellular non-membrane-bound organelle 2.1
Nonmembrane-bound organelle 2.1
Asymptomatic vs. Control
CXC chemokine 190.8
Small chemokine, C-X-C 153.4
Small chemokine, interleukin-8-like 65.2
Chemokine activity 58.8
Chemokine receptor binding 57.6
Inflammatory response 51.1
SCY 46.8
G-protein-coupled receptor binding 38.4
Locomotory behavior 20.2
Inflammatory response 12.8
Behavior 12.0
Response to wounding 9.0
Immune response 8.4
Immune system process 6.3
Secreted 4.9
Direct protein sequencing 3.7
Affected vs. Asymptomatic
Ligase activity, forming phosphoric ester bonds 48.1
Double-stranded RNA binding 18.2
Domain: helix-loop-helix motif 7.9
Basic helix-loop-helix dimerisation region (bHLH) 7.4
Helix-loop-helix DNA-binding 6.9
HLH 6.8
DNA-binding region: basic motif 6.3
Immune response 6.0
Membrane lipid biosynthetic process 5.2
Compositionally biased region: pro-rich 2.8
Immune response 2.8
RNA-binding 2.5
Immune system process 2.4
RNA binding 2.3
Defense response 2.2
Table 3. Expression fold-change in affected and asymptomatic
carriers relative to healthy controls
Gene Fold-change/affected Fold-change/asymptomatic
CXCL9 14.1 (11.2–17.8) 137.8 (113.5–167.4)
CXCL10 6.4 (5.5–7.4) 186.9 (154.7–225.8)
CXCL11 2.1 (1.7–2.5) 113.8 (102.7–126.2)
STATH 2.4 (2.0–2.8) 225.4 (206.2–246.2)
LOC91431 0.7 (0.6–0.8) 3.0 (2.8–3.3)
PRIC285 0.5 (0.4–0.6) 0.8 (0.7–0.9)
LPP 0.8 (0.7–1.0) 1.0 (0.8–1.1)
Only the samples analyzed on microarrays were considered.
Fig. 1. Validation of the expression of the chemokines through RT-PCR. The
expression levels of CXCL9, CXCL10, and CXCL11 were calculated relative to
the mean value from normal controls in the function of residual number of
D4Z4. (A) In affected patients, the rank correlations are 1.000* (CXCL9), 1.000*
(CXCL10), and 0.800*** (CXCL11); while the line correlations are 0.933**
(CXCL9), 0.730*** (CXCL10), and 0.805*** (CXCL11). (B) In asymptomatic
carriers, the rank correlations are –0,464*** (CXCL9), –0.564*** (CXCL10),
and –0.527*** (CXCL11); while the line correlations are –0.595*** (CXCL9),
–0,004*** (CXCL10), and –0.191*** (CXCL11). *, P 0.0001; **, P 0.07; ***,
P  0.1.
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(from families 1 to 5, Table S7) shared the 4qA allele and the
same SNP in D4Z4 (G). In addition, the 4qA161 haplotype was
carried in all families tested, with the exception of family 4, in
which the affected individual has the 4qA161/4qA166 haplo-
types, while the asymptomatic carrier has the 4qA159/4qA166
haplotypes (data not shown).
microRNAs in FSHD. MicroRNAs (miRNAs) are a class of small
noncoding RNAs that are increasingly recognized for their
ability to regulate gene expression posttranscriptionally. Among
other targets, miRNAs in skeletal muscle regulate the expression
of transcription factors and signaling mediators important for
muscle biology, which in turn can influence proliferation and
differentiation during myogenesis (26, 27).
The expression profiles of miRNAs in 10 different groups of
muscle disorders, including FSHD, were recently compared (28)
and 62 miRNAs that were differentially expressed in FSHD
muscle—all up-regulated—were identified. The predicted tar-
gets for these differentially expressed miRNAs were compared
to the gene products identified here as down-regulated in FSHD
patients, compared to healthy controls. MAMI (meta mir:target
inference) was used to predict the targets for the dysregulated
miRNAs. Several different miRNAs target the same gene (Table
S8), such as ATG16L1, EPAS1, and PCDH9, which are down-
regulated in biopsy samples from affected patients. These same
genes, ATG16L1, EPAS1, and PCDH9, are also down-regulated
in affected individuals relative to asymptomatic carriers (see
Table S2), which suggests that their down-regulation by miRNAs
may be linked to the pathophysiology of FSHD. Perhaps signif-
icantly, most of these predicted targets take part in histone
acetylation and the synthesis of GPI anchors, both of which are
dysregulated in affected patients vs. healthy controls (see Table 2).
Discussion
Although FSHD was among the first of the muscular dystrophies
to have its locus mapped, the molecular mechanism leading to
the disease is still unclear. The unspecific histological alterations
in muscle and the high clinical variability observed among
patients do not give any clues about a possible mechanism
underlying FSHD. One possible way to understand the pathol-
ogy would be to examine the differences in the expression of
genes in patients with FSHD and in their close relations, who are
asymptomatic carriers. The present study is unique in making
such a comparison, which minimizes the effects deriving from
differences in genetic background, and likely gives more consis-
tent and reliable results with microarray analysis (29, 30). In
addition, all muscle biopsies were collected by the same physi-
cian and were processed in the same way, keeping variations
from technical sources to a minimum. The results support the
evidence that the expression of some genes in FSHD, and
particular those at chromosome 4q, is abnormal in FSHD
patients.
The finding that the genes from the chemokine cluster on
4q21, that are located more than 100 Mbp from D4Z4 repeats,
have a similar expression pattern (CXCL9  CXCL10 
CXCL11) in all tested affected patients through RT-PCR sug-
gests that these 3 chemokines may be under control of the same
regulators in FSHD patients, in contrast to asymptomatic car-
riers. The IFN--induced chemokines CXCL9, CXCL10, and
CXCL11 are ligands for CXCR3 receptor, and are thought to
Fig. 2. Relative expression of the other genes validated through RT-PCR in function of the number of D4Z4 repeats. The calculated correlation coefficients for
the expression level and the number of repeats for STATH (A) in affected patients are 0.8000*** (rank) and 0.2645***(line) and in asymptomatic carriers are
–0.7537** (rank) and –0.4417***(line); for LOC91431 (B) in affected patients are 0.2000*** (rank) and 0.6908*** (line) and in asymptomatic carriers are
–0.8208** (rank) and –0.8280** (line); for LPP (C) in affected patients are 1.000* (rank) and 0.7503*** (line) and in asymptomatic carriers are –0.6669*** (rank)
and –0.7650*** (line); for PRIC285 (D) in affected patients are 0.2000*** (rank) and –0.1361*** (line) and in asymptomatic carriers are 0.5643*** (rank) and
0.4008*** (line). *, P  0.0001; **, P  0.08; ***, P  0.1.
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play a key role in directing activated T cells and other cell types
(such as natural killer cells and macrophages) to sites of inflam-
mation. The up-regulation of these chemokines have not been
described in either FSHD or other forms of muscular dystrophy
(31–35), suggesting that their expression is unlikely to be linked
to inflammatory cell infiltrates. Moreover, the muscle histology
from asymptomatic carriers looks similar to the normal controls,
not showing a major inflammatory component, while in affected
patient muscle it is possible to observe general dystrophic
features (Fig. S1). The fact that there was no difference in the
expression levels of these chemokines as well as the other genes
validated—STATH, LOC91431, LPP, and PRIC285—between
affected patients and asymptomatic carriers when additional
samples were included, lessens the likelihood that these genes
could be suppressing the FSHD phenotype in asymptomatic
carriers. On the other hand, our microarray and RT-PCR data
suggest that the contraction of repeats in affected patients and
asymptomatic carriers might disturb the gene expression in cis.
This observation is supported by the finding that the contracted
allele is significantly hypomethylated in both affected individuals
and asymptomatic carriers (19). These studies did not look at the
differential expression of FRG1 or DUX4 in FSHD patient
biopsies. There was evidence from the microarray data that
indicated that from chromosome 4q35,ANKRD37 and F11 genes
are differentially expressed when compared with affected pa-
tients and asymptomatic individuals, suggesting that these 2
groups may have some specific differences on 4q35. In the 4
families tested, it appeared that the affected patients and related
asymptomatic carriers share the same 4qA161 haplotype. Thus,
these polymorphisms by themselves cannot explain the patho-
genicity linked to the contraction of D4Z4 repeats, and other
factors, perhaps acting in cis, are likely to be important in the
disease mechanism. Further studies concerning the differences
between affected patients and asymptomatic carriers are of
utmost importance and will certainly help in our knowledge
about factors necessary to trigger FSHD.
The data presented here indicated that the biological process
that may be specifically impaired in FSHD patients involves the
synthesis of GPI anchors. The structure of the GPI anchor is
composed of short chains of sugars, specifically mannose and
glucosamine, which are assembled in the endoplasmic reticulum
and linked to the inositide residues of phosphatidylinositol. After
synthesis, the entire glycolipid is transferred to C-terminal
regions of proteins posttranslationally, thereby anchoring these
proteins to the outer leaflet of the cell membrane, where they
tend to associate with lipid rafts (36). GPI anchors also have roles
in membrane diffusion, intracellular protein sorting, and signal-
ing (37). A major subclass of rafts is caveolae, which are
invaginations of the cell membrane characterized by the abun-
dance of caveolin. Caveolae contain clusters of GPI-anchored
proteins, the most well-studied of which is the folate receptor.
However, evidence also exists for the presence of other GPI-
anchored proteins, such as alkaline phosphatase, Thy-1, and
prion PrP(C) in caveolae (38). No caveolae abnormalities in
muscle plasma membranes from FSHD patients were found in
one study (39). However, alterations in the sarcolemmal reor-
ganization in muscle tissue from FSHD patients have been
reported (40). The steps in GPI assembly, and the enzymes that
carry them out, are highly conserved. The genes found to be
down-regulated in biopsies from FSHD patients presented here,
and which take part in this biological process, are involved in the
catalytic steps of the GPI biosynthetic pathway. The importance
of GPI anchoring in mammals is underscored by the fact that
abrogation of GPI biosynthesis results in embryonic lethality
(41). Defects in O-glycan biosynthesis are associated with con-
genital muscular dystrophies; further studies concerning alter-
ations in the GPI anchor and other glycan structures from
caveolae and other proteins associated with the sarcolemma in
FSHD should be pursued.
The changes in gene expression observed here may also be
linked to changes in histone acetylation, which occur only in
affected patients and not in asymptomatic carriers. Histone
modifications are likely to control the structure and/or function
of the chromatin fiber. The pattern of histone modification may
correlate with transcriptional repression/activation and also
global chromatin dynamics (42). Although previous studies (43,
44) on histone H4 acetylation levels in the proximal region of
D4Z4 did not find any difference between affected individuals
and healthy controls, the specific state of the chromatin at the
D4Z4 repeats of chromosome 4q35 has not yet been studied in
affected patients because of the lack of specific primers, but such
studies could yield interesting findings.
Our study suggests that changes in the expression of miRNAs
may also be pathogenic in FSHD. Our results are consistent with
another study that profiled the expression of miRNAs in FSHD,
and suggest that the down-regulation of mRNA levels encoding
ATG16L1, EPAS1, and PCDH9 in affected individuals, but not
in asymptomatic carriers or healthy controls, may be mediated
at least in part by increases in the levels of miRNA that target
these gene products.
In summary, there appears to be a profound difference in the
transcriptional regulation between affected patients and asymp-
tomatic carriers. The contraction of D4Z4 repeats seems to
affect the transcription of genes at 4q, in both groups, but they
suggest that factors in other regions of the genome are also
associated with the pathogenesis of FSHD. Nevertheless, per-
turbations in histone acetylation may affect the chromatin
structure specifically in the affected patients, leading to the
pathogenic changes associated with the disease. Similarly, dif-
ferences in the synthesis of GPI-anchored proteins may also be
linked to muscle pathology in affected individuals. In addition,
our results indicate that the miRNAs play a role in the regulatory
network in FSHD, increasing the complexity of the mechanism
underlying the disease. The study of expression profiles from
asymptomatic carriers is a unique approach that has revealed
these new and interesting findings, and in the future should
contribute to a better understanding of FSHD.
Materials and Methods
Muscle Biopsies. Muscle biopsies were taken from related members (affected,
asymptomatic carrier, and normal control) belonging to 5 unrelated families
(see families 1 to 5 in Table S7). Asymptomatic carriers were considered those
older than 30 years old, without any FSHD clinical signal, but who share the
deleted fragment in common with their clinically affected relative. Additional
biopsies were also collected from single members of additional families
(families 6 to 10 in Table S7). The asymptomatic carriers corresponding to
number 16, 17, 19, and 20 samples also have at least one related affected who
shares the same FSHD allele. The presence of mosaicism had been previously
excluded through pulsed field-gel electrophoresis. For the microarray studies,
muscle biopsies were taken from the biceps in 3 families and from the deltoid
in the remaining 2 families, because the clinically affected patients had a
severe atrophy. The same muscle was taken from all individuals within each
family to minimize variability. One portion of each biopsy was frozen for
molecular studies and another for histological analysis (see Fig. S1). All of the
biopsies were taken at the Human Genome Research Center (University of Sa˜o
Paulo, Brazil) after informed consent approved by the institutional review
board.
RNA Isolation. The frozen muscle tissue was ground in dry ice in a mortar, and
the total RNA was isolated from muscle tissue using the TRIReagent method
(Molecular Research Center, Inc.) following the manufacturer’s protocol. For
details, see the SI Text.
Microarray Assay. mRNA microarray was performed with the Human Genome
U133 Plus 2.0 chip (Affymetrix), following the procedures for target labeling
according to ‘‘One-Cycle Eukaryotic Target Labeling’’ protocol as described in
the SI Text.
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Microarray Data Analysis. A probe-by-probe differential fold analysis was
performed between any 2 sample populations—control vs. asymptomatic,
control vs. affected, asymptomatic vs. affected—using a geometric logarith-
mic fold method. For details see the SI Text.
Gene Ontology Enrichment Analysis. We performed a gene ontology (GO)
enrichment analysis of the list of probes of interest using DAVID 2008 (http://
david.abcc.ncifcrf.gov) data freeze June 2008. These lists were restricted to
probes that had an Entrez gene assignment and duplicated/redundant Entrez
genes were removed. The background gene set was 19,501 unique Entrez
genes assayed on the Affymetrix Human Genome GeneChip Human Genome
U133 Plus 2.0 microarray. We identified ontologic categories that had a Fisher
exact P-value (EASE score) 0.05 (45). This analysis was performed on the
significantly dysregulated genes.
RT-PCR Validation of Microarray Data. The validation of microarray results was
done through quantitative RT-PCR, using TaqMan Gene Expression Assays
(Applied Biosystems) as described in the SI Text.
Characterization of 4q35 Alleles.After isolation of DNA from peripheral blood,
the DNA was digested with HindIII and separated by electrophoresis on
agarose gels, followed by transfer to Hybond membrane (GE Healthcare) by
Southern blotting. The membrane was hybridized with probes that specifi-
cally distinguish these alleles, as described in ref. 10. The D4Z4 SNP and the
SSLP of all individuals studied in the present work were defined as in ref. 18.
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